Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-07-02FDA Approved: TALVEY — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for TALVEY (talquetamab) from Janssen Biotech, Inc. The supplemental approval updates the labeling f…
-
FDA approval · 2024-07-02FDA Approved: TECVAYLI — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for TECVAYLI (teclistamab-cqyv) from Janssen Biotech, Inc.
-
FDA approval · 2024-07-01FDA Approved: NINLARO — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for NINLARO (ixazomib) submitted by Takeda Pharmaceuticals America, Inc.
-
CLINICAL_TRIALS trial_result · 2024-07-01Clinical Trial Update: Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure [Phase 2]
A Phase 2 trial of a daratumumab-based regimen for newly diagnosed multiple myeloma with kidney failure has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-07-01Clinical Trial Update: Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma [Phase 1]
Phase 1 trial evaluating autologous CD8+ T cells engineered to express an anti-BCMA CAR for multiple myeloma has been terminated.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-07-01Clinical Trial Update: Bleeding in Multiple Myeloma
A clinical trial registry entry for a study on bleeding in patients with multiple myeloma; the trial is not yet recruiting.
-
CLINICAL_TRIALS trial_result · 2024-06-28Clinical Trial Update: A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX15 With Daratumumab in Male Subjects [Phase 1]
Phase 1 study comparing pharmacokinetics, safety, tolerability, and immunogenicity of HLX15 versus daratumumab in male subjects with multipl…
-
CLINICAL_TRIALS trial_result · 2024-06-28Clinical Trial Update: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
The clinical trial update reports safety and efficacy findings for ALLO-605, an anti-BCMA allogeneic CAR T-cell therapy, in relapsed/refract…
-
CLINICAL_TRIALS trial_result · 2024-06-28Clinical Trial Update: LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma [NA]
A clinical trial update for LCAR-M61S and LCAR-M61D in Relapsed/Refractory Multiple Myeloma; the study is currently not recruiting.
-
CLINICAL_TRIALS trial_result · 2024-06-27Clinical Trial Update: Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients [Phase 2]
Phase 2 study evaluating somatostatin receptor imaging in relapsing and refractory multiple myeloma has completed.
-
CLINICAL_TRIALS research · 2024-06-24Clinical Trial Update: Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not
A recruiting clinical trial evaluating outcomes for primary multiple myeloma patients who achieved minimal residual disease negativity after…
-
CLINICAL_TRIALS research · 2024-06-21Clinical Trial Update: Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma [Phase 2]
This phase 2 clinical trial update describes two regimens for newly diagnosed multiple myeloma: daratumumab with ixazomib and dexamethasone,…
-
CLINICAL_TRIALS trial_result · 2024-06-18Clinical Trial Update: Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) [Phase 2]
Phase 2 MATCH subprotocol evaluating AZD9291 (osimertinib) as a targeted treatment for cancers with EGFR genetic changes; the trial is curre…
-
CLINICAL_TRIALS trial_result · 2024-06-18Clinical Trial Update: Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1) [Phase 2]
Phase 2 trial evaluating Erdafitinib (JNJ-42756493) for cancers with FGFR amplifications; the study includes advanced and refractory lymphom…
-
CLINICAL_TRIALS trial_result · 2024-06-18Clinical Trial Update: QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
The QUILT-3.020 trial evaluating ALT-801 in relapsed or refractory multiple myeloma has been terminated, with results posted on 2024-06-18.
-
CLINICAL_TRIALS research · 2024-06-17Clinical Trial Update: COVID19 OutcomeS in Myeloma and the Impact of VaCcines
Clinical trial update noting an active-not-recruiting study investigating COVID-19 outcomes in patients with multiple myeloma and the impact…
-
CLINICAL_TRIALS research · 2024-06-17Clinical Trial Update: Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma [Phase 1, Phase 2]
A Phase 1/2 trial evaluating selinexor in combination with VRd (bortezomib, lenalidomide, dexamethasone) for high-risk newly diagnosed multi…
-
CLINICAL_TRIALS research · 2024-06-17Clinical Trial Update: ASH Research Collaborative Data Hub
The ASH Research Collaborative Data Hub trial is currently enrolling by invitation for Sickle Cell Disease and Multiple Myeloma. This entry …
-
CLINICAL_TRIALS trial_result · 2024-06-14Clinical Trial Update: Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients [Phase 1, Phase 2]
This clinical trial update reports results from a Phase 1/2 study of isatuximab in combination with cemiplimab in relapsed/refractory multip…
-
CLINICAL_TRIALS research · 2024-06-14Clinical Trial Update: Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients [Phase 1]
Phase 1 clinical trial evaluating PET imaging with 18F-fludarabine for initial assessment and end-treatment evaluation in symptomatic multip…
-
CLINICAL_TRIALS research · 2024-06-14Clinical Trial Update: A Survey on NINLARO Risk Management Plan (RMP) Material Utilization Among Pharmacists in Japan
A completed survey in Japan evaluating how pharmacists utilize Risk Management Plan materials for ixazomib (NINLARO) with results posted in …
-
CLINICAL_TRIALS trial_result · 2024-06-13Clinical Trial Update: Prevention of Treatment Induced Neuropathy in Multiple Myeloma [Phase 2]
Phase 2 clinical trial update on preventing treatment-induced neuropathy in multiple myeloma; the study has completed and results were poste…
-
CLINICAL_TRIALS trial_result · 2024-06-13Clinical Trial Update: Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib [Phase 2]
A phase 2 trial evaluating ixazomib citrate in patients with relapsed multiple myeloma that is not refractory to bortezomib has completed an…
-
CLINICAL_TRIALS research · 2024-06-13Clinical Trial Update: Clinical Outcomes and Prognostic Factors in Multiple Myeloma Patients
This clinical trial update discusses clinical outcomes and prognostic factors in patients with multiple myeloma. The study is not yet recrui…
-
CLINICAL_TRIALS trial_result · 2024-06-13Clinical Trial Update: Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma [Phase 1]
This clinical trial update notes the completion of a Phase 1 study of ISB 1342, a CD38/CD3 bispecific antibody, in subjects with relapsed/re…